Wound care and regenerative medicine company Acelity said today that it filed a registration statement with the SEC for another attempt at an initial public offering.
The registration comes on the heels of a failed attempt at an IPO, launched in August of 2015, in which the company looked to fetch up to $1 billion. The IPO didn’t turn out, however, and the company spiked it in December 2016.
San Antonio-based Acelity, formerly known as KCI, was acquired for $6.1 billion by Apax Partners and a pair of Canadian pension funds in a leveraged buyout in November 2011. The company, which makes wound care products, later folded KCI sister company LifeCell and acquisition Systagenix into the Acelity brand.
Acelity produces advanced wound care products and has a portfolio available in 90 countries globally, the company said. The products are used in more than 800,000 procedures annually worldwide, according to Acelity’s website.
The company said that it plans to restructure so that its affiliate KCI Holdings will become the holding company of the businesses currently conducted by Acelity L.P. and its subsidiaries.
Acelity said that the number of shares and price for the offering has not yet been determined, according to a press release.
J.P. Morgan, Goldman Sachs and BofA Merrill Lynch are acting as joint book-runners for the offering.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.